Please find enclosed herewith the Financial Results for the Quarter and Year Ended March 31, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab Ltd submitted its audited results for Q4 and FY25, with the Board declaring an unmodified (clean) auditor opinion from C.N. Patel & Co. On a standalone basis, revenue from operations fell to ₹701.90 lakhs in FY25 from ₹744.04 lakhs in FY24, and the company slipped into a small loss of ₹(8.36) lakhs in Q4 FY25 versus a ₹17.33 lakh profit a year ago. Full-year standalone profit stood at ₹139.46 lakhs (vs ₹182.35 lakhs). On a consolidated basis (which includes subsidiary Naxpar Pharma, the main revenue driver), revenue was nearly flat at ₹18,773.78 lakhs (FY24: ₹18,871.12 lakhs), but profit after tax jumped to ₹1,153.92 lakhs from ₹962.48 lakhs, with EPS rising to ₹10.05 from ₹8.38. Q4 FY25 consolidated revenue grew to ₹4,903.85 lakhs (vs ₹4,636.93 lakhs) and consolidated PAT rose to ₹292.58 lakhs (vs ₹224.53 lakhs). Operating cash flow stayed healthy at ₹3,230.15 lakhs on a consolidated level.
The clean audit opinion removes any governance red flags. Consolidated earnings growth is positive for shareholders, but the weak standalone Q4 loss and modest top-line softness may draw limited attention since most of the business value sits in the subsidiary Naxpar Pharma.